Results 171 to 180 of about 21,298 (206)

Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

Nature Medicine, 2021
Binghe Xu, Pin Zhang, Xichun Hu
exaly  

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

New England Journal of Medicine, 2020
Patrick Neven, Peter A Fasching, Michelino De Laurentiis   +2 more
exaly  

Fulvestrant

Reactions Weekly, 2016
openaire   +2 more sources

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

Lancet Oncology, The, 2021
Hope S Rugo, Eva Ciruelos, Patrick Neven
exaly  

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

Lancet Oncology, The, 2022
Renaud Sabatier, Florian Clatot, Céline Callens   +2 more
exaly  

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

Lancet, The, 2016
Lawrence Panasci, Alexey Manikhas, Kwok-Leung Cheung   +2 more
exaly  

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

JAMA Oncology, 2020
George W Sledge, Masakazu Toi, Patrick Neven   +2 more
exaly  

Fulvestrant

Reactions Weekly
openaire   +2 more sources

Abemaciclib/​fulvestrant

Reactions Weekly, 2023
openaire   +2 more sources

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

New England Journal of Medicine, 2018
Igor N Bondarenko, Seock-Ah Im, Norikazu Masuda   +2 more
exaly